Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Operating Expenses (2016 - 2025)

Spero Therapeutics' Operating Expenses history spans 10 years, with the latest figure at $9.9 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 73.1% year-over-year to $9.9 million; the TTM value through Dec 2025 reached $60.5 million, down 50.15%, while the annual FY2025 figure was $60.5 million, 50.15% down from the prior year.
  • Operating Expenses reached $9.9 million in Q4 2025 per SPRO's latest filing, down from $13.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $36.8 million in Q4 2024 to a low of $9.9 million in Q4 2025.
  • Average Operating Expenses over 5 years is $23.3 million, with a median of $23.5 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: soared 98.03% in 2023, then plummeted 73.1% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $30.2 million in 2021, then dropped by 28.86% to $21.5 million in 2022, then rose by 6.85% to $23.0 million in 2023, then surged by 59.93% to $36.8 million in 2024, then tumbled by 73.1% to $9.9 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Operating Expenses are $9.9 million (Q4 2025), $13.4 million (Q3 2025), and $16.6 million (Q2 2025).